BioSpace News Archive

Innovent Biologics, Group. (“Innovent”) (HKEX: 01801), today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial (clinicaltrials.gov, NCT05003531) of recombinant anti-interleukin 23p19 subunit antibody injection (R & D code: IBI112) in China.

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, received the resignation of Mr Peter Anastasiou.

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA ® (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting.

Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $3 billion of shares of its common stock in the open market or in negotiated transactions

Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics’ lead investigational drug, were published online September 16, 2021 in the journal BLOOD.

Ocugen, Inc. (NASDAQ: OCGN), today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time.

Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), today announced the presentation of new data at the ongoing 2021 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Charlotte, North Carolina.